Overview

Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

Status:
Active, not recruiting

Trial end date:
2023-01-15

Target enrollment:

Participant gender:

Summary

There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil (MMF) showed promising results in those patients but still, the data available are in form of case reports. So, investigators will investigate the efficiency of MMF against a well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic anemia in SLE patients.

Phase:

Phase 3

Details

Lead Sponsor:

Assiut University

Treatments:

Mycophenolic Acid
Rituximab